538 related articles for article (PubMed ID: 34493592)
1. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
Hall SAL; Vogrin S; Wawryk O; Burns GS; Visvanathan K; Sundararajan V; Thompson A
Gut; 2022 Aug; 71(8):1629-1641. PubMed ID: 34493592
[TBL] [Abstract][Full Text] [Related]
2. Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels.
Hall SAL; Burns GS; Anagnostou D; Vogrin S; Sundararajan V; Ratnam D; Levy MT; Lubel JS; Nicoll AJ; Strasser SI; Sievert W; Desmond PV; Ngu MC; Angus P; Sinclair M; Meredith C; Matthews G; Revill PA; Jackson K; Littlejohn M; Bowden DS; Locarnini SA; Visvanathan K; Thompson AJ
Aliment Pharmacol Ther; 2022 Jul; 56(2):310-320. PubMed ID: 35521992
[TBL] [Abstract][Full Text] [Related]
3. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
4. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
[TBL] [Abstract][Full Text] [Related]
5. Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B.
Choi HSJ; Hirode G; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong GLH; Brakenhoff SM; Chien RN; Feld JJ; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1513-1522.e4. PubMed ID: 35863683
[TBL] [Abstract][Full Text] [Related]
6. Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B.
Chen CH; Peng CY; Hu TH; Wang JH; Hung CH; Lu SN
Aliment Pharmacol Ther; 2023 Aug; 58(3):334-345. PubMed ID: 37265196
[TBL] [Abstract][Full Text] [Related]
7. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV; Rigopoulou EI; Papatheodoridi M; Zachou K; Xourafas V; Gatselis N; Hadziyannis E; Vlachogiannakos J; Manolakopoulos S; Dalekos GN
Antivir Ther; 2018; 23(8):677-685. PubMed ID: 30044765
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy.
Lin MJ; Su TH; Liu CJ; Yang HC; Chen CL; Liou JM; Tseng TC; Liu CH; Hong CM; Chen PJ; Kao JH
J Formos Med Assoc; 2023 Jul; 122(7):564-573. PubMed ID: 36872131
[TBL] [Abstract][Full Text] [Related]
9. A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study.
Peng CW; Jeng WJ; Yang HI; Liu YC; Chien RN; Liaw YF
J Gastroenterol Hepatol; 2022 Nov; 37(11):2164-2172. PubMed ID: 35869752
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
11. Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients.
Na JH; Kim JH; Choe WH; Kwon SY; Yoo BC
Korean J Gastroenterol; 2021 Jun; 77(6):285-293. PubMed ID: 34158448
[TBL] [Abstract][Full Text] [Related]
12. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
Chen CH; Hsu YC; Lu SN; Hung CH; Wang JH; Lee CM; Hu TH
J Viral Hepat; 2018 May; 25(5):590-597. PubMed ID: 29274189
[TBL] [Abstract][Full Text] [Related]
13. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B.
Song DS; Jang JW; Yoo SH; Kwon JH; Nam SW; Bae SH; Choi JY; Yoon SK
Clin Infect Dis; 2021 Aug; 73(4):e892-e903. PubMed ID: 33417679
[TBL] [Abstract][Full Text] [Related]
14. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
Ma TL; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
PLoS One; 2019; 14(10):e0222221. PubMed ID: 31584951
[TBL] [Abstract][Full Text] [Related]
15. Higher HBeAg-reversion virological relapse and lower sustained remission after treatment cessation in tenofovir-treated HBeAg-positive patients.
Chen YC; Hsu CW; Chien RN
J Med Virol; 2023 Nov; 95(11):e29213. PubMed ID: 37933418
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.
Kuo MT; Hu TH; Hung CH; Wang JH; Lu SN; Tsai KL; Chen CH
Aliment Pharmacol Ther; 2019 Jan; 49(2):218-228. PubMed ID: 30484881
[TBL] [Abstract][Full Text] [Related]
17. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
Kao JH; Jeng WJ; Ning Q; Su TH; Tseng TC; Ueno Y; Yuen MF
Hepatol Int; 2021 Aug; 15(4):833-851. PubMed ID: 34297329
[TBL] [Abstract][Full Text] [Related]
18. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
[TBL] [Abstract][Full Text] [Related]
19. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Viganò M; Mangia G; Lampertico P
Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
